C14TKL-1 in Focus C14TKL-1 (Arg-His-Arg-Thr-Pro-Met-Phe-Tyr-Gly-Leu-Met-NH2) acts as a NK-1 agonist, with broad expression in the human peripheral system
Inject into the thigh, abdomen, or upper arm, and rotate the injection site each week
A common community-reported on-cycle profile: Phase 2 trial titration moved faster: 2 mg/week for weeks 1-4, 4 mg/week for weeks 5-8, 8 mg/week for weeks 9-12, then 12 mg/week from week 13 onward
But heres the crucial piece: Most people who stop the medication without a long-term plan regain some or all of their weight
Use 29 to 31 gauge insulin syringes for subcutaneous GHK-Cu injections
Without insurance, out-of-pocket costs for the drugs can run hundreds of dollars each time you fill a prescription